ADVANCE
Phase 3 Completed
595 enrolled 19 charts
CALYPSO
Phase 3 Completed
344 enrolled
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Phase 2 Completed
336 enrolled
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Phase 2 Completed
271 enrolled 32 charts
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Phase 3 Completed
266 enrolled 58 charts
SIGNATURE
Phase 3 Completed
235 enrolled 23 charts
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Phase 1 Completed
36 enrolled
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
666 enrolled 110 charts
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
1,101 enrolled 46 charts
Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
Phase 1 Unknown
57 enrolled
CLEAR
Phase 3 Completed
46 enrolled 27 charts
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Terminated
2,867 enrolled 77 charts
REFINE
Phase 3 Completed
310 enrolled 32 charts
Tofacitinib Ointment For Chronic Plaque Psoriasis
Phase 2 Completed
476 enrolled 33 charts
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Phase 3 Completed
95 enrolled 37 charts
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
901 enrolled 56 charts
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Phase 3 Completed
600 enrolled